Viridian Therapeutics, Inc.\DE
VRDN · XNASCIK 1590750fmd_1X9VHXANXNDR7CHYXBJ1TDMZW1Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2026, 54 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 3 | 4 | 8 | 4 | 1 | 3 | 2 | 0 | 0 | 71 |
| Cost of revenue | 3 | – | – | – | – | – | – | – | – | – |
| Gross profit | 1 | – | – | – | – | – | – | – | – | – |
| Realized investment gains (losses) | – | – | 0 | 0 | 0 | – | – | – | – | – |
| Research and development | 14 | 20 | 30 | 35 | 28 | 57 | 101 | 160 | 238 | 339 |
| Selling, general and administrative | 10 | – | – | – | – | – | – | 95 | 61 | 95 |
| Total operating expenses | 20 | 31 | 41 | 46 | 111 | 83 | 136 | 255 | 299 | 434 |
| Operating income | (17) | (27) | (33) | (42) | (110) | (80) | (134) | (254) | (299) | (363) |
| Interest expense | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 2 | 5 |
| Interest and investment income | – | – | – | – | – | 0 | 5 | 18 | 32 | 27 |
| Other non-operating income (expense) | 0 | 0 | 1 | 1 | 0 | 0 | 4 | 17 | 29 | 21 |
| Income tax expense | – | – | – | – | – | – | – | – | – | 0 |
| Net income | (17) | (27) | (33) | (42) | (111) | (79) | (130) | (238) | (270) | (343) |
| Net income to common shareholders | (17) | (27) | (33) | (42) | (111) | (79) | – | – | – | – |